BEND, Ore., Aug. 7, 2018 — /D.M.O. Newswire/ — EVIO Inc. ("EVIO" or the "Company"), (OTC:EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry in North America, announced that its Massachusetts lab has submitted its license application to the state's Cannabis Control Commission and is seeking approval to be licensed as an independent testing laboratory under the Commission's recently adopted adult use regulations. This is on the heels of the recent announcement of the lab receiving ISO 17025 accreditation.
Massachusetts law requires that all recreational marijuana products bear a seal showing they have been tested by a Commission-licensed independent laboratory for contaminants and potency levels.
"With the cannabis industry continuing to ramp up in Massachusetts, the lab is poised to play a major role being one of only three labs that have started the licensing process," said Lori Glauser, COO of EVIO. "We are preparing for the rapidly increased demand for testing services as the Commonwealth's adult-use cannabis market is expected to exceed $1 billion by 2021."
About EVIO Inc.
EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company's EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply. The Company's EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system.
For more information, visit www.eviolabs.com.
Safe Harbor Statement
Any statements in this press release that are not statements of historical fact maybe considered to be forward-looking statements. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov or www.eviolabs.com.